Showing 1 - 5 results of 5 for search 'Mark J Murphy', query time: 0.03s Refine Results
  1. 1
    The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration

    The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration by Martine Baumann, Benoît Lack, Isabelle Guillaumat, Mark J. Murphy, Markus A. Riederer

    Published 2022-01-01
    Get full text
    Article
  2. 2
    In Vitro Characterization of Sphingosine 1-Phosphate Receptor 1 (S1P<sub>1</sub>) Expression and Mediated Migration of Primary Human T and B Cells in the Context of Cenerimod, a Novel, Selective S1P<sub>1</sub> Receptor Modulator

    In Vitro Characterization of Sphingosine 1-Phosphate Receptor 1 (S1P<sub>1</sub>) Expression and Mediated Migration of Primary Human T and B Cells in the Context of Cenerimod, a No... by Lisa Schlicher, Paulina Kulig, Audrey von Münchow, Mark J. Murphy, Marcel P. Keller

    Published 2022-01-01
    Get full text
    Article
  3. 3
    MLL becomes functional through intra-molecular interaction not by proteolytic processing.

    MLL becomes functional through intra-molecular interaction not by proteolytic processing. by Akihiko Yokoyama, Francesca Ficara, Mark J Murphy, Christian Meisel, Chikako Hatanaka, Issay Kitabayashi, Michael L Cleary

    Published 2013-01-01
    Get full text
    Article
  4. 4
    LO-016 The multifaceted immunomodulatory properties of cenerimod, a selective S1P1 receptor modulator, target three key aspects of SLE pathogenesis

    LO-016 The multifaceted immunomodulatory properties of cenerimod, a selective S1P1 receptor modulator, target three key aspects of SLE pathogenesis by Peter Cornelisse, Daniel S Strasser, Marianne M Martinic, Mark J Murphy, Ouali Berkani, Clélia Cahuzac, Thomas F Hoyler

    Published 2023-07-01
    Article
  5. 5
    Cenerimod, a selective S1P1 receptor modulator, improves organ-specific disease outcomes in animal models of Sjögren’s syndrome

    Cenerimod, a selective S1P1 receptor modulator, improves organ-specific disease outcomes in animal models of Sjögren’s syndrome by Estelle Gerossier, Saba Nayar, Sylvie Froidevaux, Charlotte G. Smith, Celine Runser, Valentina Iannizzotto, Enrico Vezzali, Gabin Pierlot, Ulrich Mentzel, Mark J. Murphy, Marianne M. Martinic, Francesca Barone

    Published 2021-11-01
    Get full text
    Article

Search Tools: